微信公众号
About Novelty Pharmaceutical
Novelty Pharmaceutical Co.,Ltd was founded by several doctoral graduates from both China and abroad. Its founder, Kris Tseng, was born in Taiwan, China, and went to the United States immediately after completing his undergraduate studies. He subsequently earned a master’s degree and a Ph.D., and served as CEO of a Hong Kong‑listed company on the Main Board. To gain a deeper understanding of the Chinese market, he enrolled in Fudan University’s EMBA program in 2007 and obtained an MBA in 2010. In 2021, Dr. Zeng established Novelty Pharmaceutical Co.,Ltd focusing on three key areas—“pharmaceuticals,” “skin,” and “permeation”—to continuously explore non‑invasive, painless, simple, and effective methods for delivering drugs into the body, while developing two major product lines: light medical aesthetics and clinical healthcare. Starting in 2022, the company began leveraging cutting‑edge “soluble microcrystal technology” to create the Shudiyaya microcrystal product series.
As the pioneer of soluble microneedle technology, Novelty Pharmaceutical Co.,Ltd has successfully launched its fourth-generation “sharp‑arc” microneedle platform, achieving truly painless transdermal drug delivery. The company boasts proprietary mass‑production processes and equipment, leveraging MEMS‑based solidification molding to be the first to develop an ultra‑large 200 cm² pure sodium hyaluronate microchip—its single‑step forming area far surpasses that of competing products from Japan and South Korea (7–10 cm²). Production costs have been reduced to less than half of those associated with conventional manufacturing methods. Following rigorous technical due diligence by leading international manufacturers, Novelty Pharmaceutical Co.,Ltd ranks first worldwide in three key performance metrics: needle sharpness, needle mechanical strength, and single‑step forming area.
Novelty Pharmaceutical Co.,Ltd currently operates a 100,000‑class cosmetics manufacturing facility and has completed construction of a 100,000‑class GMP‑compliant medical device production plant; another GMP‑certified facility is under development. The company holds 22 patents, has established CRO partnerships with leading universities such as China Pharmaceutical University and Fudan University, and has successfully launched more than 20 application‑specific projects. Moving forward, the company will continue to serve top-tier platforms through its Taiwan‑based OEM model, maintain technological leadership through ongoing R&D and process innovation, and expand into the medical sector via collaborations on new dosage forms approved by the CFDA, providing global clients with end‑to‑end soluble microneedle solutions—from R&D to manufacturing.
Deep industry expertise
Elite team
Annual sales revenue
Corporate culture
Corporate Vision
Pioneering a new era of transdermal drug delivery and becoming a global enabler of personalized medicine.
Content Interpretation: The vision articulates the company’s long-term aspirations and ultimate goals. “A New Era of Transdermal Drug Delivery” precisely positions the company as an industry disruptor, leveraging microneedle and microcrystal technologies to revolutionize conventional drug‑delivery methods. Meanwhile, “A Global Enabling Platform for Personalized Medicine” transcends the role of a mere product supplier, outlining a future ecosystem in which the company serves as a technology platform, providing innovative drug‑delivery solutions to pharmaceutical companies and R&D institutions—aligning closely with the listed company’s platform‑based value proposition.
Corporate Mission
Committed to overcoming bottlenecks in transdermal delivery technologies, we develop novel delivery systems that are safe, highly effective, and user‑friendly, driving innovation in biopharmaceutical materials and ensuring that every treatment is more precise and convenient.
- Content Interpretation: The mission articulates the fundamental purpose of the enterprise and the core of its day-to-day operations.
- Overcoming Bottlenecks: Embodying the spirit of scientific research in tackling core technological challenges.
- Safe, efficient, and user-friendly: the gold standard for product development, encompassing efficacy, safety, and user experience.
- Empowering biopharmaceutical innovation: This directly targets collaborative models with pharmaceutical companies and vaccine‑development institutions, representing a key growth driver for the future.
- Making every treatment more precise and convenient: elevating social value, connecting patients with health and well-being, and enhancing brand warmth.
Core Values
Innovation and Transformation Leadership
We dare to explore uncharted territories in science, defining industry standards through sustained technological originality. We refuse to settle for imitation, striving instead for fundamental innovation—from materials and processes to applications.
Jointly Creating Value
We adopt an open stance to foster deep collaboration with our supply-chain partners. We are not merely suppliers; we are enablers, driving innovation alongside our partners to co‑create maximum value in healthcare.
Hold oneself accountable through action.
We maintain a profound reverence for life and health. We integrate quality and safety into every detail of research, development, and production, uphold the highest ethical standards, and assume unwavering responsibility to patients, partners, and society.
Diligence and pragmatism
While gazing at the stars, we keep our feet firmly on the ground. By staying focused on our goals and approaching our work with a scientific, rational mindset, meticulous craftsmanship, and efficient execution, we transform cutting-edge technologies into stable, reliable commercial products.
Qualification Certificate
Novelty Pharmaceutical Co.,Ltd
Address: East Side, 4th Floor, Building 9, Nengda Biopharmaceutical Science and Technology Park, No. 9 Xindong Road, Economic and Technological Development Zone, Chongchuan District, Nantong City, Jiangsu Province
Scan it
Follow us
Visit the mobile website
Website Development:China Enterprise DynamicsNantongSEO